Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lamictal · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lamotrigine Tablets 25 mg |
| 2 | ACTIVE_COMPARATOR | Lamictal® Tablets 25 mg |
| Name | Type | Description |
|---|---|---|
| Lamotrigine Tablets 25 mg | DRUG | 2x25mg, single dose fed |
| Lamictal® Tablets 25 mg | DRUG | 2x25mg, single dose fed |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evenin...
Lamictal is a small molecule drug being developed by Viatris Inc. (ticker: VTRS). It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers, and it is an investigational product, not yet approved for any indication.
Lamictal is being studied for use in healthy volunteers. The current clinical trials are bioavailability studies comparing Lamictal tablets to a reference product. No therapeutic indication has been established for Lamictal in these trials, as they are focused on healthy participants.
Lamictal is being developed by Viatris Inc., which trades under the ticker VTRS. The company is conducting Phase 1 clinical trials for Lamictal, which is a small molecule drug. Viatris is responsible for the ongoing clinical development of this investigational product.
Lamictal is in Phase 1 clinical development. There are two completed Phase 1 trials, and no active trials are currently ongoing. The drug is investigational and has not been approved by regulatory authorities. It is being studied in healthy volunteers.
Lamictal has two completed Phase 1 clinical trials: NCT00647751, a food study of lamotrigine tablets 25 mg compared to Lamictal tablets 25 mg, and NCT00650208, a fasting study of the same comparison. Both trials enrolled healthy volunteers in the United States, with a total enrollment of 55 participants.
Lamictal is the brand name for lamotrigine. The clinical trials for Lamictal compare lamotrigine tablets to Lamictal tablets, indicating that lamotrigine is the active ingredient. Lamictal is the proprietary name used by the developer, Viatris Inc., for this small molecule drug.